Cargando…

The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment

Background and objectives: Anemia is common in multiple myeloma (MM) and is caused by a complex pathomechanism, including impaired iron homeostasis. Our aim is to evaluate the biomarkers of iron turnover: serum soluble transferrin receptor (sTfR) and hepcidin-25 in patients at various stages of MM i...

Descripción completa

Detalles Bibliográficos
Autores principales: Banaszkiewicz, Małgorzata, Małyszko, Jolanta, Batko, Krzysztof, Koc-Żórawska, Ewa, Żórawski, Marcin, Dumnicka, Paulina, Jurczyszyn, Artur, Woziwodzka, Karolina, Maleszka, Aleksandra, Krzanowski, Marcin, Kraśniak, Andrzej, Drożdż, Ryszard, Krzanowska, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955231/
https://www.ncbi.nlm.nih.gov/pubmed/35334593
http://dx.doi.org/10.3390/medicina58030417
_version_ 1784676286584586240
author Banaszkiewicz, Małgorzata
Małyszko, Jolanta
Batko, Krzysztof
Koc-Żórawska, Ewa
Żórawski, Marcin
Dumnicka, Paulina
Jurczyszyn, Artur
Woziwodzka, Karolina
Maleszka, Aleksandra
Krzanowski, Marcin
Kraśniak, Andrzej
Drożdż, Ryszard
Krzanowska, Katarzyna
author_facet Banaszkiewicz, Małgorzata
Małyszko, Jolanta
Batko, Krzysztof
Koc-Żórawska, Ewa
Żórawski, Marcin
Dumnicka, Paulina
Jurczyszyn, Artur
Woziwodzka, Karolina
Maleszka, Aleksandra
Krzanowski, Marcin
Kraśniak, Andrzej
Drożdż, Ryszard
Krzanowska, Katarzyna
author_sort Banaszkiewicz, Małgorzata
collection PubMed
description Background and objectives: Anemia is common in multiple myeloma (MM) and is caused by a complex pathomechanism, including impaired iron homeostasis. Our aim is to evaluate the biomarkers of iron turnover: serum soluble transferrin receptor (sTfR) and hepcidin-25 in patients at various stages of MM in relation with markers of anemia, iron status, inflammation, renal impairment and burden of the disease and as predictors of mortality. Materials and methods: Seventy-three MM patients (six with smoldering and 67 with symptomatic disease) were recruited and observed for up to 27 months. Control group included 21 healthy individuals. Serum sTfR and hepcidin were measured with immunoenzymatic assays. Results: MM patients with and without anemia had higher sTFR compared to controls, while only anemic patients had higher hepcidin-25. Both hepcidin-25 and sTfR were higher in anemic than non-anemic patients. Higher hepcidin-25 (but not sTfR) was associated with increasing MM advancement (from smoldering to International Staging System stage III disease) and with poor response to MM treatment, which was accompanied by lower blood hemoglobin and increased anisocytosis. Neither serum hepcidin-25 nor sTfR were correlated with markers of renal impairment. Hepcidin-25 predicted blood hemoglobin in MM patients independently of other predictors, including markers of renal impairment, inflammation and MM burden. Moreover, both blood hemoglobin and serum hepcidin-25 were independently associated with patients’ 2-year survival. Conclusions: Our results suggest that hepcidin-25 is involved in anemia in MM and its concentrations are not affected by kidney impairment. Moreover, serum hepcidin-25 may be an early predictor of survival in this disease, independent of hemoglobin concentration. It should be further evaluated whether including hepcidin improves the early diagnosis of anemia in MM.
format Online
Article
Text
id pubmed-8955231
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89552312022-03-26 The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment Banaszkiewicz, Małgorzata Małyszko, Jolanta Batko, Krzysztof Koc-Żórawska, Ewa Żórawski, Marcin Dumnicka, Paulina Jurczyszyn, Artur Woziwodzka, Karolina Maleszka, Aleksandra Krzanowski, Marcin Kraśniak, Andrzej Drożdż, Ryszard Krzanowska, Katarzyna Medicina (Kaunas) Article Background and objectives: Anemia is common in multiple myeloma (MM) and is caused by a complex pathomechanism, including impaired iron homeostasis. Our aim is to evaluate the biomarkers of iron turnover: serum soluble transferrin receptor (sTfR) and hepcidin-25 in patients at various stages of MM in relation with markers of anemia, iron status, inflammation, renal impairment and burden of the disease and as predictors of mortality. Materials and methods: Seventy-three MM patients (six with smoldering and 67 with symptomatic disease) were recruited and observed for up to 27 months. Control group included 21 healthy individuals. Serum sTfR and hepcidin were measured with immunoenzymatic assays. Results: MM patients with and without anemia had higher sTFR compared to controls, while only anemic patients had higher hepcidin-25. Both hepcidin-25 and sTfR were higher in anemic than non-anemic patients. Higher hepcidin-25 (but not sTfR) was associated with increasing MM advancement (from smoldering to International Staging System stage III disease) and with poor response to MM treatment, which was accompanied by lower blood hemoglobin and increased anisocytosis. Neither serum hepcidin-25 nor sTfR were correlated with markers of renal impairment. Hepcidin-25 predicted blood hemoglobin in MM patients independently of other predictors, including markers of renal impairment, inflammation and MM burden. Moreover, both blood hemoglobin and serum hepcidin-25 were independently associated with patients’ 2-year survival. Conclusions: Our results suggest that hepcidin-25 is involved in anemia in MM and its concentrations are not affected by kidney impairment. Moreover, serum hepcidin-25 may be an early predictor of survival in this disease, independent of hemoglobin concentration. It should be further evaluated whether including hepcidin improves the early diagnosis of anemia in MM. MDPI 2022-03-11 /pmc/articles/PMC8955231/ /pubmed/35334593 http://dx.doi.org/10.3390/medicina58030417 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Banaszkiewicz, Małgorzata
Małyszko, Jolanta
Batko, Krzysztof
Koc-Żórawska, Ewa
Żórawski, Marcin
Dumnicka, Paulina
Jurczyszyn, Artur
Woziwodzka, Karolina
Maleszka, Aleksandra
Krzanowski, Marcin
Kraśniak, Andrzej
Drożdż, Ryszard
Krzanowska, Katarzyna
The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title_full The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title_fullStr The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title_full_unstemmed The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title_short The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment
title_sort key role of hepcidin-25 in anemia in multiple myeloma patients with renal impairment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955231/
https://www.ncbi.nlm.nih.gov/pubmed/35334593
http://dx.doi.org/10.3390/medicina58030417
work_keys_str_mv AT banaszkiewiczmałgorzata thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT małyszkojolanta thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT batkokrzysztof thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT koczorawskaewa thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT zorawskimarcin thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT dumnickapaulina thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT jurczyszynartur thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT woziwodzkakarolina thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT maleszkaaleksandra thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krzanowskimarcin thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krasniakandrzej thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT drozdzryszard thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krzanowskakatarzyna thekeyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT banaszkiewiczmałgorzata keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT małyszkojolanta keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT batkokrzysztof keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT koczorawskaewa keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT zorawskimarcin keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT dumnickapaulina keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT jurczyszynartur keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT woziwodzkakarolina keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT maleszkaaleksandra keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krzanowskimarcin keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krasniakandrzej keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT drozdzryszard keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment
AT krzanowskakatarzyna keyroleofhepcidin25inanemiainmultiplemyelomapatientswithrenalimpairment